ID   S12A3_HUMAN             Reviewed;        1021 AA.
AC   P55017; A8MSJ2; C9JNN9;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   10-MAY-2017, entry version 164.
DE   RecName: Full=Solute carrier family 12 member 3;
DE   AltName: Full=Na-Cl cotransporter;
DE            Short=NCC;
DE   AltName: Full=Na-Cl symporter;
DE   AltName: Full=Thiazide-sensitive sodium-chloride cotransporter;
GN   Name=SLC12A3; Synonyms=NCC, TSC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANTS GTLMNS TRP-209;
RP   GLY-264; LEU-349; ARG-421; ASN-486; CYS-496; SER-561 DEL; VAL-588;
RP   VAL-630; HIS-655; LEU-655; ARG-741; PRO-850 AND GLN-955, VARIANT
RP   THR-728, AND FUNCTION.
RX   PubMed=8528245; DOI=10.1038/ng0196-24;
RA   Simon D.B., Nelson-Williams C., Bia M.J., Ellison D., Karet F.E.,
RA   Molina A.M., Vaara I., Iwata F., Cushner H.M., Koolen M., Gainza F.J.,
RA   Gitelman H.J., Lifton R.P.;
RT   "Gitelman's variant of Bartter's syndrome, inherited hypokalaemic
RT   alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl
RT   cotransporter.";
RL   Nat. Genet. 12:24-30(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT GLY-264, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=8812482; DOI=10.1006/geno.1996.0388;
RA   Mastroianni N., de Fusco M., Zollo M., Arrigo G., Zuffardi O.,
RA   Bettinelli A., Ballabio A., Casari G.;
RT   "Molecular cloning, expression pattern, and chromosomal localization
RT   of the human Na-Cl thiazide-sensitive cotransporter (SLC12A3).";
RL   Genomics 35:486-493(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT
RP   GLY-264.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=21613606; DOI=10.1152/ajpcell.00070.2011;
RA   Cruz-Rangel S., Melo Z., Vazquez N., Meade P., Bobadilla N.A.,
RA   Pasantes-Morales H., Gamba G., Mercado A.;
RT   "Similar Effects of all WNK3 Variants upon SLC12 Cotransporters.";
RL   Am. J. Physiol. 301:C601-C608(2011).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-91, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [7]
RP   TISSUE SPECIFICITY, AND CHARACTERIZATION OF VARIANTS GTLMNS ASP-121;
RP   SER-439; CYS-475 AND ARG-1021.
RX   PubMed=26099046; DOI=10.1038/nm.3890;
RA   Wang J., Sun C., Gerdes N., Liu C., Liao M., Liu J., Shi M.A., He A.,
RA   Zhou Y., Sukhova G.K., Chen H., Cheng X.W., Kuzuya M., Murohara T.,
RA   Zhang J., Cheng X., Jiang M., Shull G.E., Rogers S., Yang C.L., Ke Q.,
RA   Jelen S., Bindels R., Ellison D.H., Jarolim P., Libby P., Shi G.P.;
RT   "Interleukin 18 function in atherosclerosis is mediated by the
RT   interleukin 18 receptor and the Na-Cl co-transporter.";
RL   Nat. Med. 21:820-826(2015).
RN   [8]
RP   VARIANTS GTLMNS ASN-62; ASP-186; TRP-209; LEU-349; SER-439; GLU-478;
RP   ASN-486; CYS-496; PRO-542; VAL-588 AND ARG-731.
RX   PubMed=8900229;
RA   Mastroianni N., Bettinelli A., Bianchetti M., Colussi G., De Fusco M.,
RA   Sereni F., Ballabio A., Casari G.;
RT   "Novel molecular variants of the Na-Cl cotransporter gene are
RT   responsible for Gitelman syndrome.";
RL   Am. J. Hum. Genet. 59:1019-1026(1996).
RN   [9]
RP   INTERACTION WITH KLHL3, AND UBIQUITINATION.
RX   PubMed=22406640; DOI=10.1038/ng.2218;
RA   Louis-Dit-Picard H., Barc J., Trujillano D., Miserey-Lenkei S.,
RA   Bouatia-Naji N., Pylypenko O., Beaurain G., Bonnefond A., Sand O.,
RA   Simian C., Vidal-Petiot E., Soukaseum C., Mandet C., Broux F.,
RA   Chabre O., Delahousse M., Esnault V., Fiquet B., Houillier P.,
RA   Bagnis C.I., Koenig J., Konrad M., Landais P., Mourani C., Niaudet P.,
RA   Probst V., Thauvin C., Unwin R.J., Soroka S.D., Ehret G., Ossowski S.,
RA   Caulfield M., Bruneval P., Estivill X., Froguel P., Hadchouel J.,
RA   Schott J.J., Jeunemaitre X.;
RT   "KLHL3 mutations cause familial hyperkalemic hypertension by impairing
RT   ion transport in the distal nephron.";
RL   Nat. Genet. 44:456-460(2012).
RN   [10]
RP   VARIANT GTLMNS PRO-623.
RX   PubMed=8954067; DOI=10.1210/jcem.81.12.8954067;
RA   Takeuchi K., Kure S., Kato T., Taniyama Y., Takahashi N., Ikeda Y.,
RA   Abe T., Narisawa K., Muramatsu Y., Abe K.;
RT   "Association of a mutation in thiazide-sensitive Na-Cl cotransporter
RT   with familial Gitelman's syndrome.";
RL   J. Clin. Endocrinol. Metab. 81:4496-4499(1996).
RN   [11]
RP   VARIANTS GTLMNS TRP-209; PRO-215; THR-226; HIS-261; HIS-560; SER-613;
RP   HIS-642; ARG-649; CYS-655; ARG-738; ARG-741; PRO-850 AND CYS-852, AND
RP   VARIANTS GLN-904 AND CYS-919.
RX   PubMed=9734597; DOI=10.1046/j.1523-1755.1998.00070.x;
RA   Lemmink H.H., Knoers N.V.A.M., Karolyi L., van Dijk H., Niaudet P.,
RA   Antignac C., Guay-Woodford L.M., Goodyer P.R., Carel J.-C., Hermes A.,
RA   Seyberth H.W., Monnens L.A.H., van den Heuvel L.P.W.J.;
RT   "Novel mutations in the thiazide-sensitive NaCl cotransporter gene in
RT   patients with Gitelman syndrome with predominant localization to the
RT   C-terminal domain.";
RL   Kidney Int. 54:720-730(1998).
RN   [12]
RP   VARIANTS GTLMNS PRO-304; SER-439; ARG-731 AND ARG-741, AND VARIANT
RP   GLN-904.
RX   PubMed=10988270; DOI=10.1161/01.HYP.36.3.389;
RA   Melander O., Orho-Melander M., Bengtsson K., Lindblad U., Rastam L.,
RA   Groop L., Hulthen U.L.;
RT   "Genetic variants of thiazide-sensitive NaCl-cotransporter in
RT   Gitelman's syndrome and primary hypertension.";
RL   Hypertension 36:389-394(2000).
RN   [13]
RP   VARIANTS GTLMNS LYS-180; GLU-569; MET-578; CYS-642 AND HIS-849.
RX   PubMed=10616841;
RA   Monkawa T., Kurihara I., Kobayashi K., Hayashi M., Saruta T.;
RT   "Novel mutations in thiazide-sensitive Na-Cl cotransporter gene of
RT   patients with Gitelman's syndrome.";
RL   J. Am. Soc. Nephrol. 11:65-70(2000).
RN   [14]
RP   VARIANTS GTLMNS PHE-154; LEU-178; GLN-209; ARG-284; VAL-313; TRP-321;
RP   TRP-334; CYS-399; LEU-555; LEU-615; GLY-642; LEU-643 AND VAL-729.
RX   PubMed=11168953; DOI=10.1046/j.1523-1755.2001.059002710.x;
RA   Cruz D.N., Shaer A.J., Bia M.J., Lifton R.P., Simon D.B.;
RT   "Gitelman's syndrome revisited: an evaluation of symptoms and health-
RT   related quality of life.";
RL   Kidney Int. 59:710-717(2001).
RN   [15]
RP   VARIANT GTLMNS LEU-643, AND VARIANT GLY-264.
RX   PubMed=11940055; DOI=10.1046/j.1365-2265.2002.01223.x;
RA   Pantanetti P., Arnaldi G., Balercia G., Mantero F., Giacchetti G.;
RT   "Severe hypomagnesaemia-induced hypocalcaemia in a patient with
RT   Gitelman's syndrome.";
RL   Clin. Endocrinol. (Oxf.) 56:413-418(2002).
RN   [16]
RP   VARIANT GTLMNS PRO-623.
RX   PubMed=12008755; DOI=10.1507/endocrj.49.91;
RA   Tajima T., Kobayashi Y., Abe S., Takahashi M., Konno M., Nakae J.,
RA   Okuhara K., Satoh K., Ishikawa T., Imai T., Fujieda K.;
RT   "Two novel mutations of thiazide-sensitive Na-Cl cotrans porter (TSC)
RT   gene in two sporadic Japanese patients with Gitelman syndrome.";
RL   Endocr. J. 49:91-96(2002).
RN   [17]
RP   VARIANTS GTLMNS GLN-158; MET-163; ARG-172; TRP-209; VAL-316; VAL-374;
RP   GLU-463; THR-464; LEU-615; TRP-615; GLY-642; HIS-642; MET-677;
RP   CYS-852; SER-852; GLY-958 AND TYR-985, AND VARIANT GLN-904.
RX   PubMed=12112667; DOI=10.1002/humu.9045;
RA   Syren M.-L., Tedeschi S., Cesareo L., Bellantuono R., Colussi G.,
RA   Procaccio M., Ali A., Domenici R., Malberti F., Sprocati M., Sacco M.,
RA   Miglietti N., Edefonti A., Sereni F., Casari G., Coviello D.A.,
RA   Bettinelli A.;
RT   "Identification of fifteen novel mutations in the SLC12A3 gene
RT   encoding the Na-Cl Co-transporter in Italian patients with Gitelman
RT   syndrome.";
RL   Hum. Mutat. 20:78-78(2002).
RN   [18]
RP   VARIANTS GTLMNS MET-60; VAL-569; CYS-642 AND HIS-849.
RX   PubMed=15069170; DOI=10.1093/ndt/gfh239;
RA   Maki N., Komatsuda A., Wakui H., Ohtani H., Kigawa A., Aiba N.,
RA   Hamai K., Motegi M., Yamaguchi A., Imai H., Sawada K.;
RT   "Four novel mutations in the thiazide-sensitive Na-Cl co-transporter
RT   gene in Japanese patients with Gitelman's syndrome.";
RL   Nephrol. Dial. Transplant. 19:1761-1766(2004).
RN   [19]
RP   VARIANTS GTLMNS TYR-90; TYR-283 AND HIS-871.
RX   PubMed=15687331; DOI=10.1210/jc.2004-1905;
RA   Lin S.-H., Shiang J.-C., Huang C.-C., Yang S.-S., Hsu Y.-J.,
RA   Cheng C.-J.;
RT   "Phenotype and genotype analysis in Chinese patients with Gitelman's
RT   syndrome.";
RL   J. Clin. Endocrinol. Metab. 90:2500-2507(2005).
RN   [20]
RP   VARIANT GTLMNS ILE-672.
RX   PubMed=16429844;
RA   Terui K., Shoji M., Yamashiki J., Hirai Y., Ishiguro A., Tsutaya S.,
RA   Kageyama K., Yasujima M., Suda T.;
RT   "A novel mutation of the thiazide-sensitive sodium chloride
RT   cotransporter gene in a Japanese family with Gitelman syndrome.";
RL   Clin. Nephrol. 65:57-60(2006).
RN   [21]
RP   VARIANTS GTLMNS LYS-68; ASN-69; HIS-145; MET-153; ASP-230; ALA-342;
RP   LEU-677 AND SER-867.
RX   PubMed=17654016; DOI=10.1080/10425170701400456;
RA   Fava C., Montagnana M., Rosberg L., Burri P., Joensson A., Wanby P.,
RA   Wahrenberg H., Hulthen U.L., Aurell M., Guidi G.C., Melander O.;
RT   "Novel mutations in the SLC12A3 gene causing Gitelman's syndrome in
RT   Swedes.";
RL   DNA Seq. 18:395-399(2007).
RN   [22]
RP   VARIANTS GTLMNS HIS-849 AND HIS-852.
RX   PubMed=17873326; DOI=10.1007/s12020-007-0024-9;
RA   Aoi N., Nakayama T., Tahira Y., Haketa A., Yabuki M., Sekiyama T.,
RA   Nakane C., Mano H., Kawachi H., Sato N., Soma M., Matsumoto K.;
RT   "Two novel genotypes of the thiazide-sensitive Na-Cl cotransporter
RT   (SLC12A3) gene in patients with Gitelman's syndrome.";
RL   Endocrine 31:149-153(2007).
RN   [23]
RP   VARIANTS GLY-264; THR-728; GLN-904 AND CYS-919, AND CHARACTERIZATION
RP   OF VARIANT CYS-919.
RX   PubMed=17885550; DOI=10.1097/HJH.0b013e3282a9be1b;
RA   Keszei A.P., Tisler A., Backx P.H., Andrulis I.L., Bull S.B.,
RA   Logan A.G.;
RT   "Molecular variants of the thiazide-sensitive Na+-Cl- cotransporter in
RT   hypertensive families.";
RL   J. Hypertens. 25:2074-2081(2007).
RN   [24]
RP   VARIANTS GTLMNS MET-60; HIS-62; GLN-83; TRP-83; ASP-121; CYS-135;
RP   CYS-145; MET-150; MET-153; PRO-157; LEU-158; MET-163; VAL-166;
RP   ARG-172; LEU-178; THR-192; ILE-194; GLN-209; ARG-235; ASN-259;
RP   PRO-272; MET-304; PRO-304; VAL-313; TRP-321; TRP-334; GLU-374;
RP   MET-382; ILE-392; CYS-399; 433-GLN--CYS-436 DELINS LEU; SER-439;
RP   SER-442; ARG-463; THR-464; CYS-475; HIS-489; CYS-507; THR-523;
RP   SER-534; LEU-536; GLY-546; LEU-555; ARG-560; ASN-566 DEL; LEU-615;
RP   CYS-642; CYS-642; GLY-642; HIS-642; LEU-643; MET-647; HIS-655;
RP   LYS-ALA-PHE-TYR-SER-ASP-VAL-ILE-713 INS; VAL-729; ARG-735; ARG-741;
RP   LEU-751; THR-824; ASN-839; PHE-849; PRO-850; CYS-852; CYS-862;
RP   THR-872; GLN-887; TRP-934; TRP-935; GLN-955; GLY-958; ARG-980;
RP   TYR-985; GLN-1009 AND ARG-1021, CHARACTERIZATION OF VARIANT GTLMNS
RP   ASP-121; ILE-392; SER-442; CYS-475; HIS-489; LEU-751 AND ARG-1021,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22009145; DOI=10.1038/ejhg.2011.189;
RA   Glaudemans B., Yntema H.G., San-Cristobal P., Schoots J., Pfundt R.,
RA   Kamsteeg E.J., Bindels R.J., Knoers N.V., Hoenderop J.G.,
RA   Hoefsloot L.H.;
RT   "Novel NCC mutants and functional analysis in a new cohort of patients
RT   with Gitelman syndrome.";
RL   Eur. J. Hum. Genet. 20:263-270(2012).
CC   -!- FUNCTION: Electroneutral sodium and chloride ion cotransporter. In
CC       kidney distal convoluted tubules, key mediator of sodium and
CC       chloride reabsorption (PubMed:21613606, PubMed:22009145). Receptor
CC       for the proinflammatory cytokine IL18. Contributes to IL18-induced
CC       cytokine production, including IFNG, IL6, IL18 and CCL2. May act
CC       either independently of IL18R1, or in a complex with IL18R1 (By
CC       similarity). {ECO:0000250|UniProtKB:P59158,
CC       ECO:0000269|PubMed:21613606, ECO:0000269|PubMed:22009145}.
CC   -!- ENZYME REGULATION: Activated by WNK3.
CC       {ECO:0000269|PubMed:21613606}.
CC   -!- SUBUNIT: Interacts with KLHL3 (PubMed:22406640). Interacts with
CC       IL18R1; this interaction is increased by IL18 treatment (By
CC       similarity). {ECO:0000250|UniProtKB:P59158,
CC       ECO:0000269|PubMed:22406640}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22009145};
CC       Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P55017-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P55017-2; Sequence=VSP_036318;
CC       Name=3;
CC         IsoId=P55017-3; Sequence=VSP_040100, VSP_036318;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in kidney
CC       (PubMed:8812482). Not detected in normal aorta, but abundantly
CC       expressed in fatty streaks and advanced atherosclerotic lesions
CC       (at protein level) (PubMed:26099046).
CC       {ECO:0000269|PubMed:26099046, ECO:0000269|PubMed:8812482}.
CC   -!- PTM: Ubiquitinated; ubiquitination is essential for regulation of
CC       endocytosis. The BCR(KLHL3) complex was initially identified as a
CC       candidate ubiquitin ligase for SLC12A3 (PubMed:22406640). However,
CC       it was later shown that it is not the case.
CC       {ECO:0000269|PubMed:22406640}.
CC   -!- PTM: Phosphorylated in response to IL18.
CC       {ECO:0000250|UniProtKB:P59158}.
CC   -!- DISEASE: Gitelman syndrome (GTLMNS) [MIM:263800]: An autosomal
CC       recessive disorder characterized by hypokalemic alkalosis in
CC       combination with hypomagnesemia, low urinary calcium, and
CC       increased renin activity associated with normal blood pressure.
CC       Patients are often asymptomatic or present transient periods of
CC       muscular weakness and tetany, usually accompanied by abdominal
CC       pain, vomiting and fever. The phenotype is highly heterogeneous in
CC       terms of age at onset and severity. Cardinal features such as
CC       hypocalciuria and hypomagnesemia might also change during the life
CC       cycle of a given patient. It has overlapping features with Bartter
CC       syndrome. {ECO:0000269|PubMed:10616841,
CC       ECO:0000269|PubMed:10988270, ECO:0000269|PubMed:11168953,
CC       ECO:0000269|PubMed:11940055, ECO:0000269|PubMed:12008755,
CC       ECO:0000269|PubMed:12112667, ECO:0000269|PubMed:15069170,
CC       ECO:0000269|PubMed:15687331, ECO:0000269|PubMed:16429844,
CC       ECO:0000269|PubMed:17654016, ECO:0000269|PubMed:17873326,
CC       ECO:0000269|PubMed:22009145, ECO:0000269|PubMed:26099046,
CC       ECO:0000269|PubMed:8528245, ECO:0000269|PubMed:8900229,
CC       ECO:0000269|PubMed:8954067, ECO:0000269|PubMed:9734597}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- MISCELLANEOUS: Target of thiazide diuretics used in the treatment
CC       of high blood pressure. {ECO:0000305|PubMed:8528245}.
CC   -!- SIMILARITY: Belongs to the SLC12A transporter family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U44128; AAC50355.1; -; mRNA.
DR   EMBL; X91220; CAA62613.1; -; mRNA.
DR   EMBL; AK315298; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC012181; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS10770.1; -. [P55017-2]
DR   CCDS; CCDS45491.1; -. [P55017-3]
DR   CCDS; CCDS58464.1; -. [P55017-1]
DR   PIR; G01202; G01202.
DR   PIR; PC4180; PC4180.
DR   RefSeq; NP_000330.2; NM_000339.2.
DR   RefSeq; NP_001119579.1; NM_001126107.1.
DR   RefSeq; NP_001119580.1; NM_001126108.1.
DR   UniGene; Hs.669115; -.
DR   ProteinModelPortal; P55017; -.
DR   BioGrid; 112448; 11.
DR   IntAct; P55017; 1.
DR   STRING; 9606.ENSP00000402152; -.
DR   ChEMBL; CHEMBL1876; -.
DR   DrugBank; DB00436; Bendroflumethiazide.
DR   DrugBank; DB00562; Benzthiazide.
DR   DrugBank; DB00880; Chlorothiazide.
DR   DrugBank; DB01119; Diazoxide.
DR   DrugBank; DB00999; Hydrochlorothiazide.
DR   DrugBank; DB00524; Metolazone.
DR   DrugBank; DB01324; Polythiazide.
DR   DrugBank; DB01325; Quinethazone.
DR   TCDB; 2.A.30.4.2; the cation-chloride cotransporter (ccc) family.
DR   iPTMnet; P55017; -.
DR   PhosphoSitePlus; P55017; -.
DR   BioMuta; SLC12A3; -.
DR   DMDM; 313104194; -.
DR   PaxDb; P55017; -.
DR   PeptideAtlas; P55017; -.
DR   PRIDE; P55017; -.
DR   DNASU; 6559; -.
DR   Ensembl; ENST00000438926; ENSP00000402152; ENSG00000070915. [P55017-2]
DR   Ensembl; ENST00000563236; ENSP00000456149; ENSG00000070915. [P55017-1]
DR   Ensembl; ENST00000566786; ENSP00000457552; ENSG00000070915. [P55017-3]
DR   GeneID; 6559; -.
DR   KEGG; hsa:6559; -.
DR   UCSC; uc002ekd.4; human. [P55017-1]
DR   CTD; 6559; -.
DR   DisGeNET; 6559; -.
DR   GeneCards; SLC12A3; -.
DR   HGNC; HGNC:10912; SLC12A3.
DR   HPA; HPA028748; -.
DR   MalaCards; SLC12A3; -.
DR   MIM; 263800; phenotype.
DR   MIM; 600968; gene.
DR   neXtProt; NX_P55017; -.
DR   OpenTargets; ENSG00000070915; -.
DR   Orphanet; 358; Gitelman syndrome.
DR   PharmGKB; PA321; -.
DR   eggNOG; KOG2083; Eukaryota.
DR   eggNOG; COG0531; LUCA.
DR   GeneTree; ENSGT00760000119053; -.
DR   HOGENOM; HOG000062855; -.
DR   HOVERGEN; HBG052851; -.
DR   InParanoid; P55017; -.
DR   KO; K14426; -.
DR   OMA; GPRKQRM; -.
DR   OrthoDB; EOG091G04G2; -.
DR   PhylomeDB; P55017; -.
DR   TreeFam; TF313191; -.
DR   Reactome; R-HSA-426117; Cation-coupled Chloride cotransporters.
DR   SIGNOR; P55017; -.
DR   ChiTaRS; SLC12A3; human.
DR   GeneWiki; Sodium-chloride_symporter; -.
DR   GenomeRNAi; 6559; -.
DR   PRO; PR:P55017; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000070915; -.
DR   CleanEx; HS_SLC12A3; -.
DR   ExpressionAtlas; P55017; baseline and differential.
DR   Genevisible; P55017; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0015378; F:sodium:chloride symporter activity; TAS:Reactome.
DR   GO; GO:0005215; F:transporter activity; ISS:UniProtKB.
DR   GO; GO:0006811; P:ion transport; TAS:Reactome.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; ISS:BHF-UCL.
DR   GO; GO:0006814; P:sodium ion transport; ISS:UniProtKB.
DR   GO; GO:0006810; P:transport; TAS:ProtInc.
DR   InterPro; IPR004841; AA-permease/SLC12A_dom.
DR   InterPro; IPR013612; AA_permease_N.
DR   InterPro; IPR018491; SLC12_C.
DR   InterPro; IPR002948; SLC12A3.
DR   InterPro; IPR004842; SLC12A_fam.
DR   PANTHER; PTHR11827:SF84; PTHR11827:SF84; 1.
DR   Pfam; PF00324; AA_permease; 1.
DR   Pfam; PF08403; AA_permease_N; 1.
DR   Pfam; PF03522; SLC12; 2.
DR   PRINTS; PR01230; NACLTRNSPORT.
DR   TIGRFAMs; TIGR00930; 2a30; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disease mutation; Glycoprotein; Ion transport; Membrane;
KW   Phosphoprotein; Polymorphism; Reference proteome; Sodium;
KW   Sodium transport; Symport; Transmembrane; Transmembrane helix;
KW   Transport; Ubl conjugation.
FT   CHAIN         1   1021       Solute carrier family 12 member 3.
FT                                /FTId=PRO_0000178026.
FT   TOPO_DOM      1    135       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    136    156       Helical. {ECO:0000255}.
FT   TRANSMEM    159    179       Helical. {ECO:0000255}.
FT   TOPO_DOM    180    218       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    219    239       Helical. {ECO:0000255}.
FT   TRANSMEM    262    282       Helical. {ECO:0000255}.
FT   TOPO_DOM    283    286       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    287    307       Helical. {ECO:0000255}.
FT   TRANSMEM    340    360       Helical. {ECO:0000255}.
FT   TOPO_DOM    361    377       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    378    398       Helical. {ECO:0000255}.
FT   TRANSMEM    453    473       Helical. {ECO:0000255}.
FT   TOPO_DOM    474    511       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    512    532       Helical. {ECO:0000255}.
FT   TRANSMEM    535    555       Helical. {ECO:0000255}.
FT   TOPO_DOM    556    577       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    578    598       Helical. {ECO:0000255}.
FT   TRANSMEM    661    681       Helical. {ECO:0000255}.
FT   TOPO_DOM    682   1021       Cytoplasmic. {ECO:0000255}.
FT   MOD_RES      43     43       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P59158}.
FT   MOD_RES      49     49       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P59158}.
FT   MOD_RES      50     50       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P59158}.
FT   MOD_RES      55     55       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P59158}.
FT   MOD_RES      60     60       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P59158}.
FT   MOD_RES      73     73       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P59158}.
FT   MOD_RES      91     91       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     124    124       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P59158}.
FT   MOD_RES     126    126       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P59158}.
FT   CARBOHYD    406    406       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    426    426       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ      95     95       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_040100.
FT   VAR_SEQ     807    807       V -> GARPSVSGAL (in isoform 2 and isoform
FT                                3). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:8528245}.
FT                                /FTId=VSP_036318.
FT   VARIANT      60     60       T -> M (in GTLMNS; dbSNP:rs371443644).
FT                                {ECO:0000269|PubMed:15069170,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039475.
FT   VARIANT      62     62       D -> H (in GTLMNS; dbSNP:rs757490496).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075931.
FT   VARIANT      62     62       D -> N (in GTLMNS).
FT                                {ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_039476.
FT   VARIANT      68     68       E -> K (in GTLMNS; dbSNP:rs763210286).
FT                                {ECO:0000269|PubMed:17654016}.
FT                                /FTId=VAR_039477.
FT   VARIANT      69     69       H -> N (in GTLMNS; dbSNP:rs780502516).
FT                                {ECO:0000269|PubMed:17654016}.
FT                                /FTId=VAR_039478.
FT   VARIANT      83     83       R -> Q (in GTLMNS; dbSNP:rs768527231).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075932.
FT   VARIANT      83     83       R -> W (in GTLMNS; dbSNP:rs201255508).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075933.
FT   VARIANT      90     90       H -> Y (in GTLMNS).
FT                                {ECO:0000269|PubMed:15687331}.
FT                                /FTId=VAR_039479.
FT   VARIANT     121    121       E -> D (in GTLMNS; 27% residual Na(+)
FT                                uptake activity; increased MAPK1/3 (ERK1/
FT                                2) phosphorylation in response to IL18;
FT                                no effect on localization at the plasma
FT                                membrane; dbSNP:rs146632606).
FT                                {ECO:0000269|PubMed:22009145,
FT                                ECO:0000269|PubMed:26099046}.
FT                                /FTId=VAR_075934.
FT   VARIANT     135    135       R -> C (in GTLMNS; dbSNP:rs749742102).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075935.
FT   VARIANT     145    145       R -> C (in GTLMNS; dbSNP:rs148945966).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075936.
FT   VARIANT     145    145       R -> H (in GTLMNS; dbSNP:rs374324018).
FT                                {ECO:0000269|PubMed:17654016}.
FT                                /FTId=VAR_039480.
FT   VARIANT     150    150       I -> M (in GTLMNS; dbSNP:rs143714318).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075937.
FT   VARIANT     153    153       V -> M (in GTLMNS; dbSNP:rs779074538).
FT                                {ECO:0000269|PubMed:17654016,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039481.
FT   VARIANT     154    154       I -> F (in GTLMNS; dbSNP:rs748547209).
FT                                {ECO:0000269|PubMed:11168953}.
FT                                /FTId=VAR_039482.
FT   VARIANT     157    157       L -> P (in GTLMNS; dbSNP:rs775047246).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075938.
FT   VARIANT     158    158       R -> L (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075939.
FT   VARIANT     158    158       R -> Q (in GTLMNS).
FT                                {ECO:0000269|PubMed:12112667}.
FT                                /FTId=VAR_039483.
FT   VARIANT     163    163       T -> M (in GTLMNS; dbSNP:rs267607050).
FT                                {ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039484.
FT   VARIANT     166    166       A -> V (in GTLMNS; dbSNP:rs779683214).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075940.
FT   VARIANT     172    172       W -> R (in GTLMNS; dbSNP:rs757792232).
FT                                {ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039485.
FT   VARIANT     178    178       S -> L (in GTLMNS; dbSNP:rs772589653).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039486.
FT   VARIANT     180    180       T -> K (in GTLMNS; dbSNP:rs146158333).
FT                                {ECO:0000269|PubMed:10616841}.
FT                                /FTId=VAR_039487.
FT   VARIANT     186    186       G -> D (in GTLMNS).
FT                                {ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_039488.
FT   VARIANT     192    192       I -> T (in GTLMNS; associated with
FT                                deletion of N-566).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075941.
FT   VARIANT     194    194       T -> I (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075942.
FT   VARIANT     209    209       R -> Q (in GTLMNS; dbSNP:rs28936388).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039489.
FT   VARIANT     209    209       R -> W (in GTLMNS; dbSNP:rs28936388).
FT                                {ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:8528245,
FT                                ECO:0000269|PubMed:8900229,
FT                                ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_007113.
FT   VARIANT     215    215       L -> P (in GTLMNS; dbSNP:rs780594361).
FT                                {ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039490.
FT   VARIANT     226    226       A -> T (in GTLMNS; dbSNP:rs774753202).
FT                                {ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039491.
FT   VARIANT     230    230       G -> D (in GTLMNS; dbSNP:rs375990084).
FT                                {ECO:0000269|PubMed:17654016}.
FT                                /FTId=VAR_039492.
FT   VARIANT     235    235       T -> R (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075943.
FT   VARIANT     259    259       D -> N (in GTLMNS; dbSNP:rs780461639).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075944.
FT   VARIANT     261    261       R -> H (in GTLMNS).
FT                                {ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039493.
FT   VARIANT     264    264       A -> G (in dbSNP:rs1529927).
FT                                {ECO:0000269|PubMed:11940055,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:17885550,
FT                                ECO:0000269|PubMed:8528245,
FT                                ECO:0000269|PubMed:8812482}.
FT                                /FTId=VAR_039494.
FT   VARIANT     272    272       L -> P (in GTLMNS; dbSNP:rs568513106).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075945.
FT   VARIANT     283    283       S -> Y (in GTLMNS).
FT                                {ECO:0000269|PubMed:15687331}.
FT                                /FTId=VAR_039495.
FT   VARIANT     284    284       K -> R (in GTLMNS).
FT                                {ECO:0000269|PubMed:11168953}.
FT                                /FTId=VAR_039496.
FT   VARIANT     304    304       T -> M (in GTLMNS; dbSNP:rs755069436).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075946.
FT   VARIANT     304    304       T -> P (in GTLMNS; dbSNP:rs753840283).
FT                                {ECO:0000269|PubMed:10988270,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039497.
FT   VARIANT     313    313       A -> V (in GTLMNS; dbSNP:rs140551719).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039498.
FT   VARIANT     316    316       G -> V (in GTLMNS; dbSNP:rs748920885).
FT                                {ECO:0000269|PubMed:12112667}.
FT                                /FTId=VAR_039499.
FT   VARIANT     321    321       R -> W (in GTLMNS; dbSNP:rs150046661).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039500.
FT   VARIANT     334    334       R -> W (in GTLMNS; dbSNP:rs770702194).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039501.
FT   VARIANT     342    342       G -> A (in GTLMNS).
FT                                {ECO:0000269|PubMed:17654016}.
FT                                /FTId=VAR_039502.
FT   VARIANT     349    349       P -> L (in GTLMNS; dbSNP:rs121909383).
FT                                {ECO:0000269|PubMed:8528245,
FT                                ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_007114.
FT   VARIANT     374    374       G -> E (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075947.
FT   VARIANT     374    374       G -> V (in GTLMNS; dbSNP:rs773669504).
FT                                {ECO:0000269|PubMed:12112667}.
FT                                /FTId=VAR_039503.
FT   VARIANT     382    382       T -> M (in GTLMNS; dbSNP:rs187885782).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075948.
FT   VARIANT     392    392       T -> I (in GTLMNS; complete loss Na(+)
FT                                uptake activity; partial loss of
FT                                localization at the plasma membrane;
FT                                dbSNP:rs748575829).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075949.
FT   VARIANT     399    399       R -> C (in GTLMNS; dbSNP:rs775931992).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039504.
FT   VARIANT     421    421       C -> R (in GTLMNS; dbSNP:rs28936387).
FT                                {ECO:0000269|PubMed:8528245}.
FT                                /FTId=VAR_007115.
FT   VARIANT     433    436       QHSC -> L (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075950.
FT   VARIANT     439    439       G -> S (in GTLMNS; does not affect MAPK1/
FT                                3 (ERK1/2) phosphorylation in response to
FT                                IL18; dbSNP:rs759377924).
FT                                {ECO:0000269|PubMed:10988270,
FT                                ECO:0000269|PubMed:22009145,
FT                                ECO:0000269|PubMed:26099046,
FT                                ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_039505.
FT   VARIANT     442    442       N -> S (in GTLMNS; 68% residual Na(+)
FT                                uptake activity; partial loss of
FT                                localization at the plasma membrane).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075951.
FT   VARIANT     463    463       G -> E (in GTLMNS).
FT                                {ECO:0000269|PubMed:12112667}.
FT                                /FTId=VAR_039506.
FT   VARIANT     463    463       G -> R (in GTLMNS; dbSNP:rs374163823).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075952.
FT   VARIANT     464    464       A -> T (in GTLMNS; dbSNP:rs201945662).
FT                                {ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039507.
FT   VARIANT     475    475       S -> C (in GTLMNS; 40% residual Na(+)
FT                                uptake activity; increased MAPK1/3 (ERK1/
FT                                2) phosphorylation in response to IL18;
FT                                no effect on localization at the plasma
FT                                membrane; dbSNP:rs373017321).
FT                                {ECO:0000269|PubMed:22009145,
FT                                ECO:0000269|PubMed:26099046}.
FT                                /FTId=VAR_075953.
FT   VARIANT     478    478       K -> E (in GTLMNS).
FT                                {ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_039508.
FT   VARIANT     486    486       D -> N (in GTLMNS; dbSNP:rs753523115).
FT                                {ECO:0000269|PubMed:8528245,
FT                                ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_007116.
FT   VARIANT     489    489       Y -> H (in GTLMNS; 48% residual Na(+)
FT                                uptake activity; no effect on
FT                                localization at the plasma membrane).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075954.
FT   VARIANT     496    496       G -> C (in GTLMNS; dbSNP:rs777612082).
FT                                {ECO:0000269|PubMed:8528245,
FT                                ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_007117.
FT   VARIANT     507    507       R -> C (in GTLMNS; dbSNP:rs369510226).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075955.
FT   VARIANT     523    523       A -> T (in GTLMNS; dbSNP:rs781137708).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075956.
FT   VARIANT     534    534       N -> S (in GTLMNS; dbSNP:rs780433336).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075957.
FT   VARIANT     536    536       F -> L (in GTLMNS; dbSNP:rs748650798).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075958.
FT   VARIANT     542    542       L -> P (in GTLMNS; dbSNP:rs574357286).
FT                                {ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_039509.
FT   VARIANT     546    546       S -> G (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075959.
FT   VARIANT     555    555       S -> L (in GTLMNS; dbSNP:rs148038173).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039510.
FT   VARIANT     560    560       P -> H (in GTLMNS).
FT                                {ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039511.
FT   VARIANT     560    560       P -> R (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075960.
FT   VARIANT     561    561       Missing (in GTLMNS).
FT                                {ECO:0000269|PubMed:8528245}.
FT                                /FTId=VAR_007118.
FT   VARIANT     566    566       Missing (in GTLMNS; associated with T-
FT                                192). {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075961.
FT   VARIANT     569    569       A -> E (in GTLMNS).
FT                                {ECO:0000269|PubMed:10616841}.
FT                                /FTId=VAR_039512.
FT   VARIANT     569    569       A -> V (in GTLMNS; dbSNP:rs79351185).
FT                                {ECO:0000269|PubMed:15069170}.
FT                                /FTId=VAR_039513.
FT   VARIANT     578    578       V -> M (in GTLMNS; dbSNP:rs139329616).
FT                                {ECO:0000269|PubMed:10616841}.
FT                                /FTId=VAR_039514.
FT   VARIANT     588    588       A -> V (in GTLMNS; dbSNP:rs121909382).
FT                                {ECO:0000269|PubMed:8528245,
FT                                ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_007119.
FT   VARIANT     613    613       G -> S (in GTLMNS).
FT                                {ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039515.
FT   VARIANT     615    615       S -> L (in GTLMNS; dbSNP:rs779160677).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039516.
FT   VARIANT     615    615       S -> W (in GTLMNS).
FT                                {ECO:0000269|PubMed:12112667}.
FT                                /FTId=VAR_039517.
FT   VARIANT     623    623       L -> P (in GTLMNS; dbSNP:rs121909385).
FT                                {ECO:0000269|PubMed:12008755,
FT                                ECO:0000269|PubMed:8954067}.
FT                                /FTId=VAR_039518.
FT   VARIANT     630    630       G -> V (in GTLMNS; dbSNP:rs28936389).
FT                                {ECO:0000269|PubMed:8528245}.
FT                                /FTId=VAR_007120.
FT   VARIANT     642    642       R -> C (in GTLMNS; dbSNP:rs200697179).
FT                                {ECO:0000269|PubMed:10616841,
FT                                ECO:0000269|PubMed:15069170,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039519.
FT   VARIANT     642    642       R -> G (in GTLMNS; dbSNP:rs200697179).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039520.
FT   VARIANT     642    642       R -> H (in GTLMNS; dbSNP:rs147901432).
FT                                {ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:22009145,
FT                                ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039521.
FT   VARIANT     643    643       P -> L (in GTLMNS; dbSNP:rs140012781).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:11940055,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039522.
FT   VARIANT     647    647       V -> M (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075962.
FT   VARIANT     649    649       T -> R (in GTLMNS).
FT                                {ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039523.
FT   VARIANT     655    655       R -> C (in GTLMNS; dbSNP:rs747249619).
FT                                {ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039524.
FT   VARIANT     655    655       R -> H (in GTLMNS; dbSNP:rs121909380).
FT                                {ECO:0000269|PubMed:22009145,
FT                                ECO:0000269|PubMed:8528245}.
FT                                /FTId=VAR_007121.
FT   VARIANT     655    655       R -> L (in GTLMNS; dbSNP:rs121909380).
FT                                {ECO:0000269|PubMed:8528245}.
FT                                /FTId=VAR_007122.
FT   VARIANT     672    672       M -> I (in GTLMNS).
FT                                {ECO:0000269|PubMed:16429844}.
FT                                /FTId=VAR_039525.
FT   VARIANT     677    677       V -> L (in GTLMNS).
FT                                {ECO:0000269|PubMed:17654016}.
FT                                /FTId=VAR_039526.
FT   VARIANT     677    677       V -> M (in GTLMNS; dbSNP:rs771326058).
FT                                {ECO:0000269|PubMed:12112667}.
FT                                /FTId=VAR_039527.
FT   VARIANT     713    713       I -> IKAFYSDVI (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075963.
FT   VARIANT     728    728       A -> T (in dbSNP:rs36049418).
FT                                {ECO:0000269|PubMed:17885550,
FT                                ECO:0000269|PubMed:8528245}.
FT                                /FTId=VAR_007123.
FT   VARIANT     729    729       G -> V (in GTLMNS; dbSNP:rs373901523).
FT                                {ECO:0000269|PubMed:11168953,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039528.
FT   VARIANT     731    731       G -> R (in GTLMNS; dbSNP:rs752101663).
FT                                {ECO:0000269|PubMed:10988270,
FT                                ECO:0000269|PubMed:8900229}.
FT                                /FTId=VAR_039529.
FT   VARIANT     735    735       P -> R (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075964.
FT   VARIANT     738    738       L -> R (in GTLMNS).
FT                                {ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039530.
FT   VARIANT     741    741       G -> R (in GTLMNS; dbSNP:rs138977195).
FT                                {ECO:0000269|PubMed:10988270,
FT                                ECO:0000269|PubMed:22009145,
FT                                ECO:0000269|PubMed:8528245,
FT                                ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_007124.
FT   VARIANT     751    751       P -> L (in GTLMNS; 54% residual Na(+)
FT                                uptake activity; no effect on
FT                                localization at the plasma membrane;
FT                                dbSNP:rs368068353).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075965.
FT   VARIANT     824    824       S -> T (in GTLMNS; dbSNP:rs146845953).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075966.
FT   VARIANT     839    839       D -> N (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075967.
FT   VARIANT     849    849       L -> F (in GTLMNS).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075968.
FT   VARIANT     849    849       L -> H (in GTLMNS; dbSNP:rs185927948).
FT                                {ECO:0000269|PubMed:10616841,
FT                                ECO:0000269|PubMed:15069170,
FT                                ECO:0000269|PubMed:17873326}.
FT                                /FTId=VAR_039531.
FT   VARIANT     850    850       L -> P (in GTLMNS; dbSNP:rs121909379).
FT                                {ECO:0000269|PubMed:22009145,
FT                                ECO:0000269|PubMed:8528245,
FT                                ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_007125.
FT   VARIANT     852    852       R -> C (in GTLMNS; dbSNP:rs373899077).
FT                                {ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:22009145,
FT                                ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039532.
FT   VARIANT     852    852       R -> H (in GTLMNS; dbSNP:rs751929135).
FT                                {ECO:0000269|PubMed:17873326}.
FT                                /FTId=VAR_039533.
FT   VARIANT     852    852       R -> S (in GTLMNS).
FT                                {ECO:0000269|PubMed:12112667}.
FT                                /FTId=VAR_039534.
FT   VARIANT     854    854       R -> K (in dbSNP:rs8060046).
FT                                /FTId=VAR_060106.
FT   VARIANT     862    862       R -> C (in GTLMNS; dbSNP:rs754505583).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075969.
FT   VARIANT     867    867       G -> S (in GTLMNS; dbSNP:rs370301695).
FT                                {ECO:0000269|PubMed:17654016}.
FT                                /FTId=VAR_039535.
FT   VARIANT     871    871       R -> H (in GTLMNS).
FT                                {ECO:0000269|PubMed:15687331}.
FT                                /FTId=VAR_039536.
FT   VARIANT     872    872       M -> T (in GTLMNS; dbSNP:rs752124879).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075970.
FT   VARIANT     887    887       R -> Q (in GTLMNS; dbSNP:rs369360334).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075971.
FT   VARIANT     904    904       R -> Q (in dbSNP:rs11643718).
FT                                {ECO:0000269|PubMed:10988270,
FT                                ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:17885550,
FT                                ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039537.
FT   VARIANT     919    919       R -> C (increases sodium transport;
FT                                dbSNP:rs12708965).
FT                                {ECO:0000269|PubMed:17885550,
FT                                ECO:0000269|PubMed:9734597}.
FT                                /FTId=VAR_039538.
FT   VARIANT     934    934       R -> W (in GTLMNS; dbSNP:rs201721269).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075972.
FT   VARIANT     935    935       R -> W (in GTLMNS; unknown pathological
FT                                significance; dbSNP:rs56125220).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075973.
FT   VARIANT     955    955       R -> Q (in GTLMNS; dbSNP:rs202114767).
FT                                {ECO:0000269|PubMed:22009145,
FT                                ECO:0000269|PubMed:8528245}.
FT                                /FTId=VAR_007126.
FT   VARIANT     958    958       R -> G (in GTLMNS; dbSNP:rs773428143).
FT                                {ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039539.
FT   VARIANT     980    980       G -> R (in GTLMNS; dbSNP:rs34803727).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075974.
FT   VARIANT     985    985       C -> Y (in GTLMNS; dbSNP:rs199849117).
FT                                {ECO:0000269|PubMed:12112667,
FT                                ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_039540.
FT   VARIANT    1009   1009       R -> Q (in GTLMNS; dbSNP:rs370175770).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075975.
FT   VARIANT    1021   1021       Q -> R (in GTLMNS; 58% residual Na(+)
FT                                uptake activity; decreased MAPK1/3 (ERK1/
FT                                2) phosphorylation in response to IL18;
FT                                partial loss of localization at the
FT                                plasma membrane; dbSNP:rs762026283).
FT                                {ECO:0000269|PubMed:22009145}.
FT                                /FTId=VAR_075976.
FT   CONFLICT    459    460       AG -> VV (in Ref. 2; CAA62613).
FT                                {ECO:0000305}.
FT   CONFLICT    539    539       S -> P (in Ref. 3; AK315298).
FT                                {ECO:0000305}.
FT   CONFLICT    766    766       D -> E (in Ref. 1; AAC50355).
FT                                {ECO:0000305}.
FT   CONFLICT    778    778       Missing (in Ref. 3; AK315298).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1021 AA;  113139 MW;  629C5A42F3234B71 CRC64;
     MAELPTTETP GDATLCSGRF TISTLLSSDE PSPPAAYDSS HPSHLTHSST FCMRTFGYNT
     IDVVPTYEHY ANSTQPGEPR KVRPTLADLH SFLKQEGRHL HALAFDSRPS HEMTDGLVEG
     EAGTSSEKNP EEPVRFGWVK GVMIRCMLNI WGVILYLRLP WITAQAGIVL TWIIILLSVT
     VTSITGLSIS AISTNGKVKS GGTYFLISRS LGPELGGSIG LIFAFANAVG VAMHTVGFAE
     TVRDLLQEYG APIVDPINDI RIIAVVSVTV LLAISLAGME WESKAQVLFF LVIMVSFANY
     LVGTLIPPSE DKASKGFFSY RADIFVQNLV PDWRGPDGTF FGMFSIFFPS ATGILAGANI
     SGDLKDPAIA IPKGTLMAIF WTTISYLAIS ATIGSCVVRD ASGVLNDTVT PGWGACEGLA
     CSYGWNFTEC TQQHSCHYGL INYYQTMSMV SGFAPLITAG IFGATLSSAL ACLVSAAKVF
     QCLCEDQLYP LIGFFGKGYG KNKEPVRGYL LAYAIAVAFI IIAELNTIAP IISNFFLCSY
     ALINFSCFHA SITNSPGWRP SFQYYNKWAA LFGAIISVVI MFLLTWWAAL IAIGVVLFLL
     LYVIYKKPEV NWGSSVQAGS YNLALSYSVG LNEVEDHIKN YRPQCLVLTG PPNFRPALVD
     FVGTFTRNLS LMICGHVLIG PHKQRMPELQ LIANGHTKWL NKRKIKAFYS DVIAEDLRRG
     VQILMQAAGL GRMKPNILVV GFKKNWQSAH PATVEDYIGI LHDAFDFNYG VCVMRMREGL
     NVSKMMQAHI NPVFDPAEDG KEASARVDPK ALVKEEQATT IFQSEQGKKT IDIYWLFDDG
     GLTLLIPYLL GRKRRWSKCK IRVFVGGQIN RMDQERKAII SLLSKFRLGF HEVHILPDIN
     QNPRAEHTKR FEDMIAPFRL NDGFKDEATV NEMRRDCPWK ISDEEITKNR VKSLRQVRLN
     EIVLDYSRDA ALIVITLPIG RKGKCPSSLY MAWLETLSQD LRPPVILIRG NQENVLTFYC
     Q
//
